You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Vinorelbine

Showing 26 - 50 of 598
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma Trial in Spain (Tucatinib, Trastuzumab,

Not yet recruiting
  • HER2-positive Metastatic Breast Cancer
  • Locally Advanced HER2 Positive Breast Carcinoma
  • Cádiz, Andalucía, Spain
  • +17 more
Jan 16, 2023

Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)

Recruiting
  • Anaplastic Large Cell Lymphoma
  • Vinorelbine
  • Vinorelbine
  • Shanghai, Shanghai, China
    Shanghai Children's Medical Center
Jul 28, 2021

Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1

Recruiting
  • Classical Hodgkin Lymphoma
  • Refractory or Relapsed Classical Hodgkin Lymphoma
  • PD-1 inhibitor
  • PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Tumors, Child, Adolescent Trial in Leiden (Ramucirumab, Cyclophosphamide, Vinorelbine)

Recruiting
  • Neoplasms
  • +2 more
  • Leiden, Netherlands
    Leids Universitair Medisch Centrum
Aug 14, 2023

NSCLC Trial in France (Atezolizumab, Vinorelbine)

Completed
  • Non-small Cell Lung Cancer
  • Aix-en-Provence, France
  • +12 more
May 11, 2022

Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Oct 7, 2023

Rhabdomyosarcoma Trial in Palo Alto, Memphis, Fort Worth (Vincristine, Dactinomycin, Cyclophosphamide)

Not yet recruiting
  • Rhabdomyosarcoma
  • Palo Alto, California
  • +2 more
Aug 27, 2023

Breast Cancer Trial in Spain (Atezolizumab + Trastuzumab + Vinorelbine)

Recruiting
  • Breast Cancer
  • Atezolizumab + Trastuzumab + Vinorelbine
  • Granada, Andalucía, Spain
  • +14 more
Mar 2, 2022

HER2-negative Breast Cancer, Advanced Breast Cancer Trial in Guangzhou (Organoid-guided treatment, Taxane, Capecitabine)

Not yet recruiting
  • HER2-negative Breast Cancer
  • Advanced Breast Cancer
  • Organoid-guided treatment
  • +5 more
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Oct 22, 2023

Breast Tumors, Malignant Tumor of the Breast Trial in Multiple Locations (Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel,

Terminated
  • Breast Neoplasms
  • Malignant Tumor of the Breast
  • Multiple Locations, Texas
    19 Sites
Nov 29, 2022

Triple Negative Breast Cancer Trial (Camrelizumab?Capecitabine/eribulin/gemcitabine/vinorelbine,

Not yet recruiting
  • Triple Negative Breast Cancer
  • (no location specified)
Nov 22, 2021

Metastatic Breast Cancer Trial (Pyrotinib, Vinorelbine, Inetetamab)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jul 11, 2021

Triple-Negative Breast Cancer Trial in Shanghai (VEGFR, nab-paclitaxel, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin)

Recruiting
  • Triple-Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Mar 28, 2023

Metastatic Breast Cancer (MBC) Trial in Nanjing, Shanghai (Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate

Recruiting
  • Metastatic Breast Cancer (MBC)
  • Paclitaxel Polymeric Micelles for Injection
  • +5 more
  • Nanjing, Jiangsu, China
  • +2 more
Nov 21, 2023

Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer

Completed
  • Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Jun 17, 2021

    Advanced Cancer, Metastatic Cervical Cancer Trial in Albuquerque, Yerevan (Balstilimab (BAL), Topotecan, Vinorelbine)

    Withdrawn
    • Advanced Cancer
    • Metastatic Cervical Cancer
    • Balstilimab (BAL)
    • +5 more
    • Albuquerque, New Mexico
    • +2 more
    Oct 3, 2022

    Metastatic Breast Cancer Trial in Shanghai (Vinorelbine, DDP)

    Recruiting
    • Metastatic Breast Cancer
    • Shanghai, China
      Fudan University Cancer Hospital
    Apr 19, 2022

    Metastatic Breast Cancer Trial in Napoli (vinorelbine, carboplatin, trastuzumab)

    Active, not recruiting
    • Metastatic Breast Cancer
    • vinorelbine
    • +2 more
    • Napoli, Italy
      Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C
    Mar 3, 2021

    NSCLC Trial in Philadelphia (device, drug, other)

    Not yet recruiting
    • NSCLC
    • Aliya Pulsed Electric Fields (PEF) ablation
    • +3 more
    • Philadelphia, Pennsylvania
      Temple University
    Oct 24, 2022

    Standard Anti-microtubule Drugs as Assessed by Early Tumor

    Recruiting
    • Breast Cancer
    • Breast Neoplasms
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Dec 10, 2021

    Breast Cancer Trial in Italy (Paclitaxel, Cyclophosphamide, Capecitabine)

    Active, not recruiting
    • Breast Cancer
    • Aviano, Italy
    • +19 more
    Aug 31, 2022

    Lung Cancer Trial in Vejle (Day 1: Cisplatin 75 mg/m2, Day 1: Vinorelbine 25 mg/m2, Day 8: Capsule vinorelbine 50 mg/m2)

    Terminated
    • Lung Cancer
    • Day 1: Cisplatin 75 mg/m2
    • +7 more
    • Vejle, Denmark
      Department of Oncology, Vejle Hospital
    Apr 28, 2021

    NSCLC Trial (QL1706 injection, Vinorelbine Tartrate, Paclitaxel)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • QL1706 injection
    • +6 more
    • (no location specified)
    Aug 3, 2022

    Triple Negative Breast Cancer Trial in Shanghai (Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel,

    Recruiting
    • Triple Negative Breast Cancer
    • Personalized treatment guided by mini-PDX and RNA sequencing
    • +5 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 18, 2022

    Metastatic Triple Negative Breast Cancer Trial (pembrolizumab, capecitabine, eribulin)

    Completed
    Has Results
    • Metastatic Triple Negative Breast Cancer
    • pembrolizumab
    • +4 more
    • (no location specified)
    Nov 9, 2021